 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12345678910111213...1920» |
- || Review, Journal: Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions. (Pubmed Central) - Mar 29, 2024
The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review...Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions...The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease.
- | Tzield (teplizumab-mzwv) / Sanofi
New P1 trial: GLP-TEP: GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (clinicaltrials.gov) - Mar 29, 2024
P1, N=24, Recruiting, Sponsor: Vanderbilt University Medical Center
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, HEOR, Monotherapy, Real-world evidence, Real-world: A Research Study Comparing RYBELSUS (clinicaltrials.gov) - Mar 28, 2024
P4, N=1262, Recruiting, Sponsor: Novo Nordisk A/S
These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease. Trial primary completion date: Feb 2024 --> Jun 2025
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants (clinicaltrials.gov) - Mar 27, 2024
P1, N=260, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2024 --> Jun 2025 Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India (clinicaltrials.gov) - Mar 27, 2024
P=N/A, N=388, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
- | Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Adherence: DIACRON: The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin (clinicaltrials.gov) - Mar 26, 2024
P=N/A, N=20, Recruiting, Sponsor: Aalborg University Hospital
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date: GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH (clinicaltrials.gov) - Mar 26, 2024
P4, N=125, Recruiting, Sponsor: Massachusetts General Hospital
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024 Trial completion date: Dec 2027 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2027
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Trial initiation date: GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH (clinicaltrials.gov) - Mar 25, 2024
P4, N=125, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Dec 2027 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2027 Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Mar 2024
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: COMMETS- Combination MCI Metabolic Syndrome (clinicaltrials.gov) - Mar 22, 2024
P2, N=80, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Mar 2024 Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date: Sit Less, Interact and Move More (SLIMM) 2 Study (clinicaltrials.gov) - Mar 21, 2024
P2, N=156, Recruiting, Sponsor: Srinvasan Beddhu
Not yet recruiting --> Recruiting Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Real-world evidence, Patient reported outcomes, Real-world: DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy (clinicaltrials.gov) - Mar 21, 2024
P=N/A, N=390, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026 Enrolling by invitation --> Active, not recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
New trial: The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes (clinicaltrials.gov) - Mar 18, 2024
P=N/A, N=60, Not yet recruiting, Sponsor: Imperial College London
- Rybelsus (semaglutide oral) / Novo Nordisk
MULTIFACTORIAL RISK REDUCTION WITH ORAL SEMAGLUTIDE VS COMPARATORS IN THE TREATMENT OF TYPE 2 DIABETES () - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_949;
- Rybelsus (semaglutide oral) / Novo Nordisk
ORAL SEMAGLUTIDE VS. METFORMIN IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMIZED CONTROLLED CLINICAL TRIAL (Station 01) - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_805;
The effect on hirsutism, HOMA-IR, fasting glucose were comparable with oral semaglutide and metformin. All other parameters including testosterone and scores of quality of life and depression remained for both semaglutide and metformin.
- Rybelsus (semaglutide oral) / Novo Nordisk
INSULIN-SPARING EFFECTS OF ORAL SEMAGLUTIDE: AN ANALYSIS OF PIONEER 8 (Station 06) - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_759;
P3
All other parameters including testosterone and scores of quality of life and depression remained for both semaglutide and metformin. Addition of oral semaglutide in pts with T2D permits a significant reduction in insulin dose, which may provide benefits (e.g. lower risk of hypoglycemia and weight gain) long-term.
- Rybelsus (semaglutide oral) / Novo Nordisk
Oral Semaglutide: a PIONEERing novel approach for T2D management (Exhibition Area) - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_679;
Addition of oral semaglutide in pts with T2D permits a significant reduction in insulin dose, which may provide benefits (e.g. lower risk of hypoglycemia and weight gain) long-term. Product theatre supported by Novo Nordisk - Oral Semaglutide: a PIONEERing novel approach for T2D management
- Rybelsus (semaglutide oral) / Novo Nordisk
Product theatre (Not Included In the Main Event CME/CPD Credit) (Exhibition Area) - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_674;
Product theatre supported by Novo Nordisk - Oral Semaglutide: a PIONEERing novel approach for T2D management Product theatre supported by Novo Nordisk - Oral Semaglutide: a PIONEERing novel approach for T2D management
- EXPLORING GASTROINTESTINAL AND HEPATOBILIARY ADVERSE EVENTS IN GLP-1 RECEPTOR AGONISTS THERAPY: A LARGE COHORT RETROSPECTIVE STUDY (140AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_8265;
Our findings indicate that GLP-1 RAs do not show an increase in GI cancer risk which is a significant clinical takeaway. However, caution and vigilance remain key, especially considering that each GLP-1 RA formulation carries its own spectrum of gastrointestinal and hepatobiliary side effects.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
DELAYED GASTRIC EMPTYING AS A CONSEQUENCE OF PATIENTS ON NEW-GENERATION GLP1-RAS: AN ANALYSIS FROM THE FAERS DATABASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1370;
Of these events, 15,399 (55.3%) were gastrointestinal (GI) issues and of these GI issues, delayed gastric emptying accounted for 2437 (15.8%) events. Of the 2437 that delayed gastric emptying, 151 (6.2%) involved an intestinal obstruction.
- COMPARATIVE EFFECTIVENESS OF GLP-1 AGONISTS FOR OBESITY MANAGEMENT IN ADULTS WITHOUT DIABETES: A NETWORK META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1361;
In our systematic review and network meta-analysis of RCTs, retatrutide 12 mg emerged as a preferred intervention among all the available GLP-1 agonists and their varying doses for obesity management in adults without diabetes. Furthermore, no difference was seen between retatrutide 12 mg and tirzepatide 15 mg, suggesting either medication can be used to produce maximum effect.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Journal: Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts. (Pubmed Central) - Mar 13, 2024
In a real-world setting, improvements in HbA1c and body weight were similar after initiation of oral or injectable semaglutide. These results may be specific to the features of the matched cohorts under investigation, with limited generalizability to populations with different characteristics.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical data, Journal, Real-world evidence, Real-world: Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada). (Pubmed Central) - Mar 12, 2024
These results may be specific to the features of the matched cohorts under investigation, with limited generalizability to populations with different characteristics. In PIONEER REAL Canada, participants treated with oral semaglutide in routine clinical practice experienced clinically relevant reductions in HbA1c and BW and increased treatment satisfaction.
- Rybelsus (semaglutide oral) / Novo Nordisk
EFFECT OF THE SEMAGLUTIDE IN ISCHEMIC ACUTE KIDNEY INJURY MODEL (MON-003; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_576;
Objectives : To evaluate the effect of oral semaglutide on renal function in rats submitted to renal ischemia/ reperfusion animal model... Semaglutide presented a renoprotective effect associated with its antioxidant role that prevented the reduction in renal function caused by the ischemic AKI.
- Rybelsus (semaglutide oral) / Novo Nordisk
Efficacy of Modern Oral Antidiabetic Drugs: A Systematic Literature Review & Network Meta-Analysis () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1734;
Our results suggest that oral semaglutide could be used as an alternative to the SGLT2i + DPP4i combination for the metabolic control of T2D patients. Additionally, oral semaglutide should be considered in overweight or obese T2D patients who require weight reduction.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Safety Profile of Semaglutide in People Aged 55 Years and Over: Pooled Data from the PIONEER, SUSTAIN, and STEP Phase 3 Clinical Programmes (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4436;
P3
Additionally, oral semaglutide should be considered in overweight or obese T2D patients who require weight reduction. Objective:We investigated the safety of semaglutide in people with T2D and/or overweight/obesity ?55 years from the phase 3a PIONEER, SUSTAIN and STEP clinical programmes.Background:The glucagon-like peptide-1 analogue semaglutide, approved for type 2 diabetes (T2D) and overweight/obesity, is being investigated in the phase 3 evoke and evoke+ trials in people with early AD aged 55
- Rybelsus (semaglutide oral) / Novo Nordisk
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4435;
P3
evoke and evoke+ are the first large-scale phase 3 trials to investigate the disease-modifying potential of semaglutide in early AD. Both studies recruited a very similar population.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide. (Pubmed Central) - Mar 4, 2024
Semaglutide is the first oral glucagon-like peptide-1 (GLP-1) analog commercially available for the treatment of type 2 diabetes...Additionally, the uptake of FcRn-targeted NPs was also observed to occur in human intestinal organoids (HIOs) expressing hFcRn through microinjection into the lumen of HIOs, resulting in potential increase of semaglutide permeability for both ligand-functionalized nanocarriers. Herein, our study demonstrates valuable data and insights that the FcRn-targeted NPs has the capacity to promote intestinal absorption of therapeutic peptides.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment change, Trial withdrawal: NN9924-7663: Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes (clinicaltrials.gov) - Mar 2, 2024
P3, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Herein, our study demonstrates valuable data and insights that the FcRn-targeted NPs has the capacity to promote intestinal absorption of therapeutic peptides. N=912 --> 0 | Not yet recruiting --> Withdrawn
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Real-world evidence, Real-world: Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7?mg or 14?mg of oral semaglutide. (Pubmed Central) - Feb 28, 2024
N=912 --> 0 | Not yet recruiting --> Withdrawn In this real-world study, patients with a pre-index HbA1c ?7% who initiated treatment with oral semaglutide with a 7 or 14?mg maintenance dose had significantly lower HbA1c levels following treatment.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date: QUEST: Lifestyle Counseling and Medication for Adolescent Weight Management (clinicaltrials.gov) - Feb 25, 2024
P2, N=120, Recruiting, Sponsor: University of Minnesota
In this real-world study, patients with a pre-index HbA1c ?7% who initiated treatment with oral semaglutide with a 7 or 14?mg maintenance dose had significantly lower HbA1c levels following treatment. Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2024 --> Jan 2026
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial: SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary (clinicaltrials.gov) - Feb 21, 2024
P=N/A, N=470, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date: PIONEER TEENS: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (clinicaltrials.gov) - Feb 15, 2024
P3, N=132, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2024 --> Jan 2026 Trial completion date: Aug 2025 --> Mar 2026
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Efficacy and safety of incretin-based therapy in MASLD patients with type 2 diabetes mellitus (New Hall) - Feb 11, 2024 - Abstract #APASL2024APASL_2942;
Background and Aim: The aim of this study was to evaluate the efficacy and safety of oral semaglutide (Sema), a GLP-1 receptor agonist, and tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated by type 2 diabetes mellitus (T2DM)... Sema and TZP treatments offered a favorable effect on MASLD as well as improving diabetic status and reducing body weight.
- | Journal: Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity. (Pubmed Central) - Jan 26, 2024
For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide...They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity.
- ARTIFICIAL INTELLIGENCE ANALYSIS OF SOCIAL MEDIA POSTS ON GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7573;
This study demonstrates the potential of AI to analyze social media data and generate insights on public perceptions of GLP-1RA. This may guide strategies for addressing barriers to GLP-1RA use and identification of new groups interested in using these medications to improve their health that may warrant further study.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
EFFECT OF SEMAGLUTIDE ON CARDIORENAL OUTCOMES BY BASELINE BODY MASS INDEX AND PRIOR CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6 (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4499;
Cardiorenal effects of semaglutide vs placebo are consistent in people with T2D at high CV risk, regardless of baseline BMI or prior CVD. This analysis combines and confirms clinical trial evidence, supporting real-world use and efficacy of semaglutide in a broad population.
- || Rybelsus (semaglutide oral) / Novo Nordisk, Mycapssa (octreotide) / Chiesi
Review, Journal: Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs. (Pubmed Central) - Jan 23, 2024
Although these two medications represent major achievements in the development of orally absorbable peptide formulations, the oral bioavailability of peptides after taking Rybelsus and Mycapssa is still only around 1%. In this article, we review the approaches and recent advances of orally bioavailable middle-to-large molecules and discuss challenges for improving their oral absorption.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Journal, Real-world evidence, Real-world: Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study. (Pubmed Central) - Jan 19, 2024
P
In this article, we review the approaches and recent advances of orally bioavailable middle-to-large molecules and discuss challenges for improving their oral absorption. People living with T2D treated with oral semaglutide in Switzerland achieved clinically significant reductions in HbA and BW, with no new safety signals.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. (Pubmed Central) - Jan 17, 2024
This article presents a summary of studies investigating SNAC technology as an absorption enhancer for a number of molecules and, in particular, explores how SNAC, once coformulated with oral semaglutide, facilitates increased absorption and bioavailability. Practical advice and dispensing information for pharmacists is also provided.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, pilocarpine / Generic mfg.
Journal: Semaglutide-associated hyposalivation: A report of case series. (Pubmed Central) - Jan 15, 2024
We are reporting for the first time hyposalivation associated with the use of semaglutide. Further prospective, larger studies are warranted to confirm these findings.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. (Pubmed Central) - Jan 15, 2024
Significant changes were observed in body mass index, fasting plasmatic glucose, blood pressure, total cholesterol, LDL and albumin to creatinine ratio, with a high rate (55%) of near-normalization of glycated hemoglobin. Our real world data confirmed the potential of the oral combination therapy dapagliflozin with semaglutide in inducing pharmacological remission of type 2 diabetes mellitus.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Does a higher dose of oral semaglutide treatment make sense? (Pubmed Central) - Jan 12, 2024
Our real world data confirmed the potential of the oral combination therapy dapagliflozin with semaglutide in inducing pharmacological remission of type 2 diabetes mellitus. No abstract available
- | Rybelsus (semaglutide oral) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Enrollment open, Trial initiation date, Metastases: Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue (clinicaltrials.gov) - Jan 12, 2024
P1/2, N=30, Recruiting, Sponsor: Dr Adnan Agha
No abstract available Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Oct 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Greater time spent with HbA1c?less than?7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies. (Pubmed Central) - Jan 9, 2024
Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Oct 2023 Oral semaglutide 7 and 14?mg resulted in greater time spent with HbA1c?less than?7.0%, and a greater likelihood of achieving and maintaining HbA1c less than?7.0% versus oral comparators.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal: A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. (Pubmed Central) - Jan 2, 2024
Oral semaglutide 7 and 14?mg resulted in greater time spent with HbA1c?less than?7.0%, and a greater likelihood of achieving and maintaining HbA1c less than?7.0% versus oral comparators. This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial (RCT) of the cognitive benefits of the combination of INI with semaglutide in individuals enriched for CVD and at high dementia risk.
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice (clinicaltrials.gov) - Jan 1, 2024
P=N/A, N=194, Recruiting, Sponsor: Novo Nordisk A/S
This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial (RCT) of the cognitive benefits of the combination of INI with semaglutide in individuals enriched for CVD and at high dementia risk. Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Mar 2024 --> Oct 2024
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date: TEAL: Treating PCOS With Semaglutide vs Active Lifestyle Intervention (clinicaltrials.gov) - Dec 31, 2023
P2/3, N=60, Active, not recruiting, Sponsor: University of Colorado, Denver
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO S-RWD). (Pubmed Central) - Dec 28, 2023
Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Mar 2024 --> Oct 2024 No abstract available
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (clinicaltrials.gov) - Dec 26, 2023
P=N/A, N=462, Active, not recruiting, Sponsor: Novo Nordisk A/S
No abstract available Recruiting --> Active, not recruiting
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice (clinicaltrials.gov) - Dec 26, 2023
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2024 --> Nov 2024